Portland biotech firm ImmuCell completes $20 million expansion

Biotech firm ImmuCell Corp. of Portland has completed construction on a $20 million, pharmaceutical-grade factory that could help reduce the amount of antibiotics used in the dairy industry, Portland Press Herald reports.

The facility is designed to produce nisin, an antibacterial peptide that ImmuCell plans to sell in purified form as a natural alternative to antibiotics for treating a disease that afflicts lactating dairy cows.

If ImmuCell succeeds in obtaining U.S. Food and Drug Administration approval, the product would give it a competitive edge in the bovine health industry. Completing the production facility is a major step toward obtaining that approval.
Read full story
Immucell Press release Nov 2017

Related Posts

University of Maine recruiting homeowners for tick surveys

ORONO, Maine — With tick season upon us, researchers at the University of Maine want to know what Mainers are doing...

25 April 2023

Maine’s oldest bioscience symposium turns 50 on MDI

Students and accomplished science leaders share research on Mt. Desert Island This April 20 marked the 50th anniversary meeting of the...

23 April 2023

Husson University students, faculty share projects at 13th annual Research Showcase

BANGOR, Maine — Today marked Husson University’s 13th annual Research and Scholarship Day. Students and faculty members at Husson shared the...

20 April 2023